PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21878835-5	2011	In a clinical study of 469 patients with HIV/AIDS treated with the NAT1/NAT2 substrate sulfamethoxazole (SMX), associations were tested between SMX-induced hypersensitivity and NAT1 *10 and *11 genotypes, together with known NAT2 polymorphisms.	Sulfamethoxazole	144-147	N-acetyltransferase 2	Homo sapiens	72-76	
22106207-0	2012	Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.	Sulfamethoxazole	35-51	N-acetyltransferase 2	Homo sapiens	13-17	
22106207-2	2012	The objective of this study was to examine the impact of N-acetyltransferase 2 (NAT2) and CYP2C9 polymorphisms on the pharmacokinetics of SMX in 118 renal transplant recipients.	Sulfamethoxazole	138-141	N-acetyltransferase 2	Homo sapiens	57-78	
22106207-2	2012	The objective of this study was to examine the impact of N-acetyltransferase 2 (NAT2) and CYP2C9 polymorphisms on the pharmacokinetics of SMX in 118 renal transplant recipients.	Sulfamethoxazole	138-141	N-acetyltransferase 2	Homo sapiens	80-84	
22106207-8	2012	SMX plasma concentrations were affected by NAT2 polymorphisms and renal dysfunction.	Sulfamethoxazole	0-3	N-acetyltransferase 2	Homo sapiens	43-47	
21878835-10	2011	Patients who carry *10/*10 and *11/*4 (fast NAT1 acetylators) were less likely to develop hypersensitivity to SMX, but this was observed only in individuals who are also carrying a slow NAT2 acetylator genotype.	Sulfamethoxazole	110-113	N-acetyltransferase 2	Homo sapiens	186-190	
16847467-1	2007	N-acetyltransferase 2 (NAT2), an important enzyme in clinical pharmacology, metabolizes antibiotics such as isoniazid and sulfamethoxazole, and catalyzes the transformation of aromatic and heterocyclic amines from the environment and diet into carcinogenic intermediates.	Sulfamethoxazole	122-138	N-acetyltransferase 2	Homo sapiens	0-21	
16847467-1	2007	N-acetyltransferase 2 (NAT2), an important enzyme in clinical pharmacology, metabolizes antibiotics such as isoniazid and sulfamethoxazole, and catalyzes the transformation of aromatic and heterocyclic amines from the environment and diet into carcinogenic intermediates.	Sulfamethoxazole	122-138	N-acetyltransferase 2	Homo sapiens	23-27	
17335581-2	2007	With the aim being to achieve individual optimization of co-trimoxazole therapy in patients with systemic lupus erythematosus (SLE), we investigated genetic polymorphisms in the NAT2 gene (which encodes the metabolizing enzyme of sulphamethoxazole).	Sulfamethoxazole	230-247	N-acetyltransferase 2	Homo sapiens	178-182	
8466547-4	1993	SMX was acetylated by both NAT1 and NAT2.	Sulfamethoxazole	0-3	N-acetyltransferase 2	Homo sapiens	36-40	
8466547-5	1993	Km values determined in hepatic cytosol for NAT1- and NAT2-mediated acetylation of SMX were 1.2 mM and approximately 5 mM, respectively, at an acetyl coenzyme A concentration of 100 microM.	Sulfamethoxazole	83-86	N-acetyltransferase 2	Homo sapiens	54-58	
8466547-10	1993	However, in the hepatocyte NAT2 variation may be an important competitive pathway which influences the extent of oxidative metabolism of SMX to its reactive hydroxylamine metabolite.	Sulfamethoxazole	137-140	N-acetyltransferase 2	Homo sapiens	27-31